Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IGM Biosciences Inc IGMS

Healthcare Biotechnology
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites.... see more

Recent & Breaking News (NDAQ:IGMS)

IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant

GlobeNewswire January 11, 2021

IGM Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2021

IGM Announces Closing of $230 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire December 11, 2020

IGM Announces Pricing of Upsized $200 million Public Offering

GlobeNewswire December 8, 2020

IGM Announces Proposed Public Offering

GlobeNewswire December 7, 2020

IGM Biosciences Presents First Clinical Data from IGM-2323 in Non-Hodgkin's Lymphoma at 2020 ASH Annual Meeting

GlobeNewswire December 5, 2020

IGM Biosciences to Host Conference Call and Webcast to Review IGM-2323 Data Presented at the 62nd Annual ASH Meeting

GlobeNewswire November 30, 2020

IGM Biosciences to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

GlobeNewswire November 23, 2020

IGM Biosciences to Present at Three Upcoming Investor Conferences

GlobeNewswire November 9, 2020

IGM Biosciences Announces Third Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire November 5, 2020

IGM Biosciences to Present First Clinical Data from IGM-2323 in Non-Hodgkin's Lymphoma at 2020 ASH Annual Meeting

GlobeNewswire November 4, 2020

IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-8444 for the Treatment of Solid Cancers and Non-Hodgkin's Lymphoma

GlobeNewswire September 30, 2020

AbCellera and IGM Biosciences Announce Multi-Year Antibody Discovery Collaboration

GlobeNewswire September 24, 2020

IGM Biosciences to Present at Four Upcoming Investor Conferences

GlobeNewswire September 2, 2020

IGM Biosciences Announces Second Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire August 6, 2020

IGM Biosciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

GlobeNewswire August 4, 2020

IGM Biosciences to Present at the Jefferies 2020 Healthcare Conference

GlobeNewswire May 28, 2020

IGM Biosciences to Present at the 2020 RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 12, 2020

IGM Biosciences Announces First Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire May 7, 2020

Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19

GlobeNewswire April 29, 2020